Altimmune Files 8-K: Board Changes and Financials

TL;DR

Altimmune's 8-K shows board/officer changes and financial updates.

AI Summary

Altimmune, Inc. filed an 8-K on November 30, 2025, reporting changes in its board of directors and officers, along with compensatory arrangements. The filing also includes financial statements and exhibits, and a Regulation FD disclosure. The company, formerly known as Pharmathene, Inc., is incorporated in Delaware and headquartered in Gaithersburg, MD.

Why It Matters

This filing indicates potential shifts in company leadership and governance, which could impact strategic direction and investor confidence.

Risk Assessment

Risk Level: low — This is a routine filing reporting on corporate governance and financial updates, with no immediate negative or positive financial implications disclosed.

Key Players & Entities

• Altimmune, Inc. (company) — Registrant
• Pharmathene, Inc. (company) — Former company name
• November 30, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Gaithersburg, MD (location) — Business address

FAQ

Key Financial Figures

• $0.0001 — ch registered Common stock, par value $0.0001 per share ALT The NASDAQ Global Marke
• $725,000 — e will receive an annual base salary of $725,000 and his target annual incentive compens

Filing Documents

• tm2532420d1_8k.htm (8-K) — 38KB
• tm2532420d1_ex10-1.htm (EX-10.1) — 48KB
• tm2532420d1_ex10-2.htm (EX-10.2) — 72KB
• tm2532420d1_ex99-1.htm (EX-99.1) — 17KB
• tm2532420d1_ex99-1img001.jpg (GRAPHIC) — 5KB
• 0001104659-25-117144.txt ( ) — 385KB
• alt-20251130.xsd (EX-101.SCH) — 3KB
• alt-20251130_lab.xml (EX-101.LAB) — 33KB
• alt-20251130_pre.xml (EX-101.PRE) — 22KB
• tm2532420d1_8k_htm.xml (XML) — 4KB

02

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 1, 2025, Altimmune, Inc. (the "Company") announced that, effective January 1, 2026 (the "Transition Date"), Vipin K. Garg, Ph.D. will transition from his role as President and Chief Executive Officer. Dr. Garg will remain with the Company as an advisor until June 30, 2026 (the "Separation Date", and the period of time between the Transition Date and the Separation Date, the "Transition Period"). On December 1, 2025, the Company announced that Jerome Durso, currently a member of the Company's Board of Directors (the "Board"), has been appointed by the Board to serve as the Company's President and Chief Executive Officer, effective as of the Transition Date. In connection with his appointment as President and Chief Executive Officer, Mr. Durso will replace Dr. Garg as the Company's principal executive officer. Mr. Durso currently serves as the Chairman of the Board and will remain in this role. On November 30, 2025, the Company and Dr. Garg entered into a Transitional Services and Release Agreement (the "Transition Agreement"). Pursuant to the Transition Agreement, Dr. Garg will step down from his role as the Company's President and Chief Executive Officer, effective as of the Transition Date. Dr. Garg will also step down as a member of the Board, effective January 31, 2026. Following the Transition Date, Dr. Garg will serve as a Advisor to the Company until the Separation Date. During the Transition Period, Dr. Garg will, among other things, assist in transitioning his duties to the new President and Chief Executive Officer and provide such other transitional services as the Company reasonably requests. Pursuant to the Transition Agreement, Dr. Garg will (i) receive severance pursuant to the terms of his employment agreement, including (A) monthly payments equal to his current base salary for 1

(a) of Regulation S-K. Mr. Durso has no family relationships with any of the Company's directors or executive

Item 404(a) of Regulation S-K. Mr. Durso has no family relationships with any of the Company's directors or executive officers.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure A press release regarding the above is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1* Transition Agreement, dated as of November 30, 2025 between the Company and Vipin Garg 10.2* Employment Agreement, dated as of November 30, 2025, by and between the Company and Jerome Durso 99.1 Press Release, dated December 1, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Management contract or compensatory plan or arrangement.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 1, 2025 ALTIMMUNE, INC. By: /s/ Gregory Weaver Gregory Weaver Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR